HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unilever Divests Dollar Shave Club, Focused On 30 ‘Power Brands’ Under New CEO’s Action Plan

Executive Summary

More brands, particularly those acquired prior to Unilever’s 2019 shift in M&A strategy, could be on the chopping block, according to CEO Hein Schumacher, who took the helm in July. His targeted action plan includes investments to accelerate innovation and increase brand and marketing support.

You may also be interested in...

Unilever’s Growth Action Plan Rooted In ‘Fewer Things Better’

CEO Hein Schumacher provided awaited detail on Unilever’s new Growth Action Plan, which seeks to leverage R&D strengths and winning technology platforms while driving productivity improvements, in an 8 February year-end sales presentation. The firm reported underlying net sales growth of 7% in fiscal 2023 to 59.6bn.

Sustainable And Ethical VMS Will Drive Consumer Health M&A In 2024

Dietary supplement brands with sustainable and ethical credentials are expected to be popular M&A targets for consumer health firms in 2024, but macroeconomic conditions will likely keep overall deal activity relatively low. 

Private Equity Firm Buys 20 ‘Iconic And Classic’ Personal Care Brands From Unilever After Suave Deal

Yellow Wood Partners LLC, a Boston-based private equity company that purchased Suave in North America from Unilever PLC early this year, has signed a binding offer to acquire 20 more personal care brands from the UK firm with its planned acquisition of Elida Beauty.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts